Corrigendum to "Phenylacetylglutamine increases the susceptibility of ventricular arrhythmias in heart failure mice by exacerbated activation of the TLR4/AKT/mTOR signaling pathway" [Int. Immunopharmacol. 116 (2023) 109795].
作者信息
Fu Hui, Kong Bin, Zhu Jun, Huang He, Shuai Wei
机构信息
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China; Cardiovascular Research Institute of Wuhan University, Wuhan 430060, Hubei, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, Hubei, China.
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China; Cardiovascular Research Institute of Wuhan University, Wuhan 430060, Hubei, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, Hubei, China.
出版信息
Int Immunopharmacol. 2025 Jan 27;146:113849. doi: 10.1016/j.intimp.2024.113849. Epub 2024 Dec 18.
PMID:39701902
Abstract
摘要
相似文献
1
Corrigendum to "Phenylacetylglutamine increases the susceptibility of ventricular arrhythmias in heart failure mice by exacerbated activation of the TLR4/AKT/mTOR signaling pathway" [Int. Immunopharmacol. 116 (2023) 109795].《“苯乙酰谷氨酰胺通过加剧TLR4/AKT/mTOR信号通路激活增加心力衰竭小鼠室性心律失常易感性”的勘误》[《国际免疫药理学》116卷（2023年）109795页]
Int Immunopharmacol. 2025 Jan 27;146:113849. doi: 10.1016/j.intimp.2024.113849. Epub 2024 Dec 18.
2
Phenylacetylglutamine increases the susceptibility of ventricular arrhythmias in heart failure mice by exacerbated activation of the TLR4/AKT/mTOR signaling pathway.苯乙酰谷氨酰胺通过加剧TLR4/AKT/mTOR信号通路的激活增加心力衰竭小鼠室性心律失常的易感性。
Int Immunopharmacol. 2023 Mar;116:109795. doi: 10.1016/j.intimp.2023.109795. Epub 2023 Feb 1.
3
Corrigendum to "Chondroprotective effects of Apolipoprotein D in knee osteoarthritis mice through the PI3K/AKT/mTOR signaling pathway" [Int. Immunopharmacol. 133 (2024) 112005].
Int Immunopharmacol. 2024 Jun 15;134:112220. doi: 10.1016/j.intimp.2024.112220. Epub 2024 May 10.
4
Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].撤回对“《对‘MLL1通过在TLR4启动子区域富集H3K4me3激活TRIF/NF-κB信号通路促进类风湿性关节炎中成纤维样滑膜细胞迁移和侵袭’的勘误》”的通知 [《国际免疫药理学》82卷（2020年）第106220页] [《国际免疫药理学》92卷（2021年）第107321页] 。
Int Immunopharmacol. 2023 Apr;117:109865. doi: 10.1016/j.intimp.2023.109865. Epub 2023 Feb 21.
5
Corrigendum to "Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway" [Int. Immunopharmacol. 128 (2024) https://doi.org/10.1016/j.intimp.2023.111466].《西维来司他通过激活PI3K/AKT/mTOR信号通路改善脓毒症诱导的心肌功能障碍》的勘误[《国际免疫药理学》128卷（2024年）https://doi.org/10.1016/j.intimp.2023.111466]
Int Immunopharmacol. 2024 Apr 20;131:111873. doi: 10.1016/j.intimp.2024.111873. Epub 2024 Mar 20.
6
Corrigendum to "Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway" [Int. Immunopharmacol. 125(Part A) (2023) 111125].《双打击淋巴瘤中的单细胞RNA测序：IMPDH2通过激活PI3K/AKT/mTOR信号通路诱导淋巴瘤进展》的勘误 [《国际免疫药理学》125(Part A) (2023) 111125]
Int Immunopharmacol. 2024 Jan 5;126:111292. doi: 10.1016/j.intimp.2023.111292. Epub 2023 Dec 1.
7
Corrigendum to "Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation" [Int. Immunopharmacol. 8 (2008) 1854-1858].
Int Immunopharmacol. 2020 Apr;81:106193. doi: 10.1016/j.intimp.2020.106193. Epub 2020 Mar 3.
8
Corrigendum to "Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis" [Int. Immunopharmacol. 77 (2019) 105968].
Int Immunopharmacol. 2020 Jul;84:106318. doi: 10.1016/j.intimp.2020.106318. Epub 2020 Feb 27.
9
Corrigendum to "Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways" [Int. Immunopharmacol. 55 (2018) 9-19].《冬凌草甲素通过抑制TLR4/p38-MAPK和TLR4/NF-κB信号通路对糖尿病肾病炎症反应的保护作用》的勘误 [《国际免疫药理学》55 (2018) 9-19]
Int Immunopharmacol. 2024 Jan 5;126:111252. doi: 10.1016/j.intimp.2023.111252. Epub 2023 Nov 30.
10
Corrigendum to "2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from the root of Averrhoa carambola L., protects against diabetic kidney disease by inhibiting TLR4/TGFβ signaling pathway" [Int. Immunopharmacol. 80 (2020) 106120].
Int Immunopharmacol. 2024 Mar 10;129:111667. doi: 10.1016/j.intimp.2024.111667. Epub 2024 Feb 12.
引用本文的文献
1
LncRNA OLMALINC promotes osteosarcoma progression through USP1-mediated autophagy suppression.长链非编码RNA OLMALINC通过USP1介导的自噬抑制促进骨肉瘤进展。
Hum Cell. 2025 Apr 18;38(3):91. doi: 10.1007/s13577-025-01221-y.
Zotero 插件